[Close]  
Pharmaceutical market research logo; 24-years of Excellence in Market Research since 1988 roundel.

Need advice? Keen to get the best deal? Call now on +44 (0)1494 771734

>

Biosimilar Market Analysis: India, China and Republic of Korea

Biosimilar Market Analysis: India, China and Republic of Korea

Table of Contents

Market Study
Published: January 2012
Pages: For full details, please email deborahf@cmsinfo.com
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 2187.50  Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Biotechnology

GBI Research?s Slidepack, ?Biosimilar Market Analysis: India, China and Republic of Korea? analyzes the competitive and product landscape for Biosimilars in India, China and Republic of Korea. Biosimilars represent one of the key breakthroughs in the pharmaceutical industry and are being used in indications varying from chemotherapy to hepatitis C and Multiple Sclerosis (MS). Biosimilar product types include Recombinant Erythropoietin, Recombinant Granulocyte Colony Stimulating Factor (G-CSF), Interferon Alpha and Beta, Human Insulin, Monoclonal Antibodies and Human Growth Hormone. There are a number of companies across India, China and Republic of Korea that are involved in the development of biosimilars targeting a broad range of indications. This presentation is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research?s team of industry experts.
Scope
Countries covered include India, China and Republic of Korea.
Data for key companies in these countries include Name and Therapeutic Class of Biosimilars Developed, List of Marketed Biologics, Biosimilars in Pipeline, Manufacturing Capacity, Expertise in Biopharmaceutical technology and Investment Details
Key players in India include Intas Biopharmaceuticals Ltd., Dr. Reddy?s Laboratories Ltd., Reliance Life Sciences Pvt. Ltd, Zenotech Laboratories Limited, Inbiopro Solutions Pvt. Ltd.USV Limited, Biocon Limited, and Zydus Cadilla Healthcare Limited, among others
Key players in China include GeneScience Pharmaceuticals Co., Ltd., Shenyang Sunshine Pharmaceutical Company Limited, Shandong GeneLeuk Biopharmaceutical Co.,ltd., Beijing SL Pharmaceutical Co., Ltd, Shanghai Huaxin High Biotechnology Inc., 3SBio Inc., and China National Biotec Group among others
Key players in Republic of Korea include LG Life Sciences, Ltd, Celltrion, Inc., Dong-A Pharmaceutical Co., Ltd, Genexine Co., Ltd., and Green Cross Corporation among others
Reasons to Buy
Develop business strategies by understanding the trends and developments that are driving the orthopedic devices market in the emerging countries.
Design and develop your biosimilars development, marketing and sales strategies in India, China and Republic of Korea.
Exploit M&A opportunities by identifying market players with the most innovative biosimilar in pipeline in these countries.
Identify key players best positioned to take advantage of emerging market opportunities.
Exploit in-licensing and out-licensing opportunities by identifying products which are most likely to ensure a robust return.

Top of Page